Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration

被引:7
|
作者
Jelin, Elma [1 ,2 ]
Wisloff, Torbjorn [3 ,4 ]
Moe, Morten C. [1 ,2 ]
Heiberg, Turid [5 ,6 ]
机构
[1] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Norwegian Inst Publ Hlth, Oslo, Norway
[4] Univ Oslo, Inst Hlth & Soc, Oslo, Norway
[5] Oslo Univ Hosp, Reg Res Support, Oslo, Norway
[6] Ostfold Univ Coll, Halden, Norway
关键词
age-related macular degeneration; anti-VEGF; intravitreal injections; patient perspective; patient-derived questionnaire; patient-reported outcome measures; ANTI-VEGF TREATMENT; EYE; RANIBIZUMAB; EXPERIENCES; IMPACT; RISK;
D O I
10.1111/aos.13847
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Studies reporting on patient perspectives during treatment of neovascular age-related macular degeneration (nAMD) are limited. Thus, the aim of this study was to develop and test psychometric performance of a patient-derived questionnaire to capture important experiences during intravitreal treatment. Methods Patients (n = 44) with at least 3-month experience of intravitreal injection treatment for nAMD identified the dimensions of priority and also performed a weighting procedure to develop a score for comparison. The questionnaire comprised two versions: one focusing on the relative importance' of the dimensions and one on the experience of the 'management' during treatment. The questionnaire was then tested for psychometric performance in a longitudinal design in newly diagnosed patients at baseline (n = 197), after three (n = 184) and six (n = 150) months of treatment. Results Of the 15 included dimensions, the following were most frequently reported: 'receive treatment to preserve vision', 'information', 'waiting time', 'trust' and 'accommodating staff. The psychometric testing showed moderate reliability (intraclass correlation coefficient: 0.65-0.67) for the two versions and high level of face validity (8.3). The dimensions, 'preserving vision', 'early access to treatment', 'pain relief', 'information about the treatment/diagnosis' and 'visual aids' were consistently reported higher in 'importance' than in 'management', at both 3 and 6 months, indicating a potential for improvement in clinical practice for these dimensions. Conclusion This study provides a brief patient-derived questionnaire, expressed with a score with good psychometric performance that can be used for monitoring during intravitreal injection treatment of nAMD patients.
引用
收藏
页码:804 / 811
页数:8
相关论文
共 50 条
  • [1] Guidance for the treatment of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Richard, Gisbert
    Augustin, Albert
    Aylward, William G.
    Bandello, Francesco
    Corcostegui, Borja
    Cunha-Vaz, Jose
    Gaudric, Alain
    Leys, Anita
    Schlingemann, Rainier O.
    [J]. ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (05): : 486 - 494
  • [2] Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
    Pitlick, Jamie M.
    Vecera, Kayla F.
    Barnes, Kylie N.
    Reski, John W.
    Forinash, Alicia B.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 290 - 296
  • [3] TREATMENT PATTERNS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Dugel, P. U.
    Arnold, R. J.
    Layton, A. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A149 - A149
  • [4] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    [J]. DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [5] Advances in the treatment of neovascular age-related macular degeneration
    Lanzetta, Paolo
    [J]. EJHP PRACTICE, 2008, 14 (06): : 17 - 20
  • [6] Neovascular Age-Related Macular Degeneration
    Veritti, Daniele
    Sarao, Valentina
    Lanzetta, Paolo
    [J]. OPHTHALMOLOGICA, 2012, 227 : 11 - 20
  • [7] Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration
    Agostini, H. T.
    Bopp, S.
    Feltgen, N.
    [J]. OPHTHALMOLOGE, 2017, 114 (05): : 476 - 480
  • [8] Treatment of age-related neovascular macular degeneration: the patient's perspective
    Mueller, S.
    Ehlken, C.
    Bauer-Steinhusen, U.
    Lechtenfeld, W.
    Hasanbasic, Z.
    Agostini, H.
    Wilke, T.
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (11) : 2237 - 2246
  • [9] Treatment of age-related neovascular macular degeneration: the patient’s perspective
    S. Müller
    C. Ehlken
    U. Bauer-Steinhusen
    W. Lechtenfeld
    Z. Hasanbasic
    H. Agostini
    T. Wilke
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 2237 - 2246
  • [10] Macular atrophy development in neovascular age-related macular degeneration
    Calugaru, Dan
    Calugaru, Mihai
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP307 - NP308